New hope for advanced GI cancer: targeted combo therapy enters phase 2
Disease control
Recruiting now
This study tests a new drug called LM-302 combined with other cancer treatments for people with advanced gastrointestinal (GI) cancer that has a specific marker (CLDN18.2). The goal is to see if the combination can shrink tumors or slow cancer growth. About 276 adults aged 18-80 …
Phase: PHASE2 • Sponsor: LaNova Medicines Zhejiang Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC